Imetelstat mechanism of action

Imetelstat (Rytelo) is indicated for the treatment of adult patients with low-to-moderate 1 risk myelodysplastic syndrome (MDS) who have transfusion-dependent anemia who have required four or more units of red blood cells within eight weeks and who have not responded or are no longer responding to the following medications: or who are not candidates for an erythropoiesis-stimulating agent (ESA).

Imetelstat comes as a powder for injection and is administered intravenously by a doctor or nurse in a medical clinic or hospital. Treatments are usually given over 2 hours every 4 weeks. Before receiving your imetelstat infusion, you will receive other medications to help you avoid side effects.

Imetelstat exerts its therapeutic effect by binding to the RNA template component of telomerase and directly inhibiting its activity. This inhibition causes the telomeres of cancer cells to gradually shorten, ultimately leading to cell death. The selectivity of imetelstat against malignant cells is due to the relatively high telomerase activity in myelodysplastic and malignant stem and progenitor cells compared with normal cells.

It is worth mentioning thatImetelstat has also demonstrated significant effects in the treatment of specific diseases. For example, Imetelstat has shown impressive efficacy in the treatment of transfusion-dependent anemia in patients with low-risk myelodysplastic syndrome (LR-MDS). In clinical trials, patients in the Imetelstat treatment group showed significant improvements in multiple key indicators compared with the placebo group, such as the 24-week RBC-TI rate.

In addition, the safety of Imetelstat has been fully evaluated. Although some adverse reactions, such as thrombocytopenia and neutropenia, may occur during treatment, most of these reactions are within controllable limits, and there are no reports of treatment-related deaths.

In general,Imetelstat provides new possibilities for the treatment of malignant tumors such as hematoma through its unique mechanism of action. With the deepening of research and the expansion of clinical applications, we have reason to expect that Imetelstat will play a greater role in the field of tumor treatment in the future.